OTCM
NMTRQ
Market cap0kUSD
Mar 12, Last price
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
9 Meters Biopharma Inc
Chart & Performance
Profile
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||
Revenues | ||||||||
Cost of revenue | 42,017 | |||||||
Unusual Expense (Income) | ||||||||
NOPBT | (42,017) | |||||||
NOPBT Margin | ||||||||
Operating Taxes | 1,749 | |||||||
Tax Rate | ||||||||
NOPAT | (43,766) | |||||||
Net income | (45,516) 23.59% | |||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
Debt | ||||||||
Debt current | 19,678 | |||||||
Long-term debt | 165 | |||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 7,196 | |||||||
Cash flow | ||||||||
Cash from operating activities | (37,243) | |||||||
CAPEX | (3) | |||||||
Cash from investing activities | (3) | |||||||
Cash from financing activities | 19,912 | |||||||
FCF | (43,706) | |||||||
Balance | ||||||||
Cash | 12,646 | |||||||
Long term investments | ||||||||
Excess cash | 12,646 | |||||||
Stockholders' equity | (212,606) | |||||||
Invested Capital | 234,736 | |||||||
ROIC | ||||||||
ROCE | ||||||||
EV | ||||||||
Common stock shares outstanding | 12,956 | |||||||
Price | 1.26 28.74% | |||||||
Market cap | 16,324 37.22% | |||||||
EV | 23,520 | |||||||
EBITDA | (42,009) | |||||||
EV/EBITDA | ||||||||
Interest | 2,667 | |||||||
Interest/NOPBT |